Plain-English translation of NCT07203352 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether combining a targeted medication—either dasatinib or sorafenib, depending on your specific cancer markers—with standard chemotherapy works better than chemotherapy alone for newly diagnosed T-cell acute lymphoblastic leukemia. All participants receive standard chemotherapy first. Then, depending on which group you're randomly assigned to, you may receive the medication in addition to further chemotherapy rounds based on how your cancer responds.
Researchers want to see if this medication can improve treatment outcomes for patients with T-cell acute lymphoblastic leukemia beyond what standard chemotherapy alone can achieve. Adding targeted treatments designed to work against specific cancer markers may help more patients go into remission and stay healthy longer.
You likely qualify if…
You likely don't qualify if…
You will first receive standard chemotherapy during an initial treatment phase. Then you'll be randomly assigned to either continue with standard chemotherapy alone or receive the targeted medication combined with chemotherapy in subsequent treatment rounds. Throughout the study, you'll have regular bone marrow tests and other evaluations to check how your cancer is responding and guide your future treatment decisions. The study involves multiple treatment courses over time with frequent monitoring at the hospital.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China
Phase
Large-scale testing
Sponsor
Nanfang Hospital, Southern Medical University
Enrollment target
~154 participants
Started
October 2025
Primary completion
December 2026
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in October 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Olivia Jiang
Nanfang Hospital, Southern Medical University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.